Zynerba pharmaceuticals, inc. (ZYNE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

7

56

255

271

278

303

629

678

810

0

0

0

Operating expenses:
Research and development

0

-

-

0

0

-

-

-

-

22,806

21,882

20,632

19,707

16,784

15,189

12,957

9,160

7,445

4,952

3,613

2,969

2,401

0

0

0

General and administrative

14,692

13,935

13,233

12,828

12,977

13,238

12,359

12,029

11,225

10,016

9,420

8,118

6,961

6,430

6,806

7,235

6,390

5,364

3,870

4,055

4,630

4,076

0

0

0

Total operating expenses

35,652

34,319

31,035

37,095

37,554

40,483

40,556

41,120

37,515

32,823

31,303

28,751

26,669

23,214

21,995

20,192

15,551

12,810

8,823

7,668

7,599

6,477

0

0

0

Loss from operations

-35,652

-34,319

-30,949

-37,009

-37,468

-40,397

-40,556

-41,120

-37,515

-32,823

-31,303

-28,751

-26,669

-23,207

-21,939

-19,936

-15,280

-12,531

-8,519

-7,038

-6,921

-5,667

0

0

0

Other income (expense):
Interest income

1,372

1,522

1,548

1,389

1,137

961

795

679

617

519

390

251

144

80

0

0

0

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

2

1

0

-1

0

0

0

Foreign exchange loss

-1,854

-145

-617

-260

-420

-474

-479

-302

-161

291

221

138

200

-189

0

0

0

-

-

-

-

-

-

-

-

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Total other income

-481

1,376

931

1,129

716

486

316

376

456

810

512

290

246

-208

5

0

0

-

0

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-23,416

-21,931

0

0

0

-

-

-

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-27

-55

0

0

0

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,516

-7,037

-6,921

-5,669

0

0

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87

0

0

0

Net loss

-36,134

-32,943

-30,018

-35,879

-36,751

-39,911

-40,239

-40,743

-37,059

-32,012

-30,790

-28,460

-26,366

-23,388

-11,052

0

0

0

-

-

-

-5,757

0

0

0

Net loss per share basic and diluted

-0.53

-0.46

-0.08

-0.50

-0.47

-0.44

-0.47

-0.89

-0.91

-0.60

-0.63

-0.64

-0.60

-0.71

-0.67

-0.70

-0.49

-0.62

-0.66

-1.12

-1.03

-0.96

-2.64

-2.29

-0.67

Basic and diluted weighted average shares outstanding

23,399

23,191

23,186

22,116

19,452

17,616

16,587

13,504

13,467

13,423

13,098

13,052

12,067

9,678

8,912

8,860

8,823

8,787

6,045

1,449

1,449

1,462

954

659

490